

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5203436

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AERAS	10/01/2018
RECEIVING PARTY DATA	
Name:	INTERNATIONAL AIDS VACCINE INITIATIVE, INC.
Street Address:	125 BROAD STREET
Internal Address:	9TH FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10004
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15628921
CORRESPONDENCE DATA	
Fax Number:	(610)640-1965
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6106512277
Email:	chill@stradley.com
Correspondent Name:	PAUL K. LEGAARD, ESQ.
Address Line 1:	30 VALLEY STREAM PARKWAY
Address Line 2:	STRADLEY RONON STEVENS & YOUNG, LLP
Address Line 4:	MALVERN, PENNSYLVANIA 19355-1481
ATTORNEY DOCKET NUMBER:	189107.01501 (3132)
NAME OF SUBMITTER:	CATHERINE HILL
SIGNATURE:	/Cathy1/
DATE SIGNED:	10/24/2018
Total Attachments: 19	
source=Aeras-IAVI Assignment#page1.tif	
source=Aeras-IAVI Assignment#page2.tif	
source=Aeras-IAVI Assignment#page3.tif	
source=Aeras-IAVI Assignment#page4.tif	

source=Aeras-IAVI Assignment#page5.tif
source=Aeras-IAVI Assignment#page6.tif
source=Aeras-IAVI Assignment#page7.tif
source=Aeras-IAVI Assignment#page8.tif
source=Aeras-IAVI Assignment#page9.tif
source=Aeras-IAVI Assignment#page10.tif
source=Aeras-IAVI Assignment#page11.tif
source=Aeras-IAVI Assignment#page12.tif
source=Aeras-IAVI Assignment#page13.tif
source=Aeras-IAVI Assignment#page14.tif
source=Aeras-IAVI Assignment#page15.tif
source=Aeras-IAVI Assignment#page16.tif
source=Aeras-IAVI Assignment#page17.tif
source=Aeras-IAVI Assignment#page18.tif
source=Aeras-IAVI Assignment#page19.tif

ASSIGNMENT OF PATENTS AND TRADEMARKS

This Assignment of Patents and Trademarks (the "Assignment") is entered into effective as of October 1, 2018 by and between Aeras, a not for profit corporation organized under the laws of the District of Columbia ("Assignor"), and International AIDS Vaccine Initiative, Inc., a not for profit corporation organized under the laws of the State of Delaware ("Assignee").

WHEREAS, Assignor and Assignee are parties to that certain Asset Transfer Agreement dated as of September 30, 2018 (the "Transfer Agreement"), pursuant to which Assignor has agreed to sell, convey, assign, transfer and deliver to Assignee: (i) all of Assignor's right, title and interest in and to the patents and patent applications listed on Schedule A hereto (collectively, the "Patents"), and (ii) all of Assignor's right, title and interest in and to the trademarks, service marks, trademark and service mark applications and trademark and service mark registrations listed on Schedule A, including all related common law rights with respect thereto (collectively, the "Trademarks"); and

WHEREAS, Assignor desires to convey assign, transfer and deliver to Assignee, and Assignee desires to purchase, acquire, receive and accept from Assignor, all of Assignor's right, title and interest in and to the Patents and Trademarks.

NOW, THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound hereby, agree as follows:

1. Assignment. Assignor does hereby sell, convey, assign, transfer and deliver unto Assignee all of Assignor's worldwide right, title and interest in, to and under:

a. All of Assignor's worldwide right, title and interest in, to and under the Patents, any and all continuations, continuations-in-part, divisions, foreign counterparts, reexaminations, reissues, renewals and extensions thereof that may hereafter be secured under the laws now or hereafter in effect in the United States and/or in any other jurisdiction, and together with all rights to sue and recover for any past infringements of any of the Patents, the same to be held and enjoyed by the Assignee, its successors and assigns from and after the date hereof as fully and entirely as the same would have been held and enjoyed by the Assignor had this assignment of the Patents not been made; and

b. All of Assignor's worldwide right, title and interest in and under the Trademarks throughout the world, including all registrations and applications thereof and the goodwill symbolized thereby, and all causes of actions, claims and demands or other rights for, or arising from, any past, present, and future infringement or other violation of the Trademarks, the same to be held and enjoyed by the Assignee, its successors and assigns from and after the date hereof as fully and entirely as the same would have been held and enjoyed by the Assignor had this assignment of the Trademarks not been made.

2. Further Assurances. Assignor further agrees, without further consideration, to cooperate with the Assignee and to execute and deliver, or use its best efforts to cause to

be executed and delivered, all such other instruments, including instruments of conveyance, assignment and transfer, and to take all such other actions as the Assignee may reasonably request from time to time, consistent with the terms of this Assignment and the Transfer Agreement, in order to effectuate the provisions and purposes of this Assignment and the transactions contemplated hereby and to permit Assignee to be duly recorded as the registered owner and proprietor of the rights hereby conveyed.

3. Counterparts; Effectiveness. This Assignment may be assigned in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Assignment shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto. For the convenience of the parties, any number of counterparts hereof may be executed, each such executed counterpart shall be deemed and original and all such counterparts together shall constitute one and the same instrument. Facsimile transmission (including the e-mail delivery of document in .pdf or similar format) of any signed original counterpart or retransmission of any signed facsimile transmission shall be deemed the same as the delivery of an original.

4. Headings. The descriptive headings contained in this Agreement are for convenience of reference only and shall not affect in any way the meaning or interpretation of this Assignment.

5. Governing Law; Jurisdiction. This Assignment will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the United State federal law preempts New York law, in which case United States federal law (including, without limitation, copyright, patent and federal trademark law) shall apply, without regard to all choice of law and conflicts of law rules.

6. Severability. If any term or other provision of this Assignment is invalid, illegal or incapable of being enforced by any law or public policy, all other terms and provisions of this Assignment shall nevertheless remain in full force and effect so long as the economic and legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Assignment so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transaction contemplated hereby are consummated as originally contemplated to the greatest extent possible, and if such modification is not possible, such provision shall be severed from this Assignment, and in either case the validity, legality and enforceability of the remaining provisions of this Assignment shall not in any way be affected or impaired thereby.

(Remainder of Page Intentionally Left Blank)

IN WITNESS WHEREOF, the undersigned have caused this Assignment and Assumption to be duly executed effective as of the date first set forth above.

ASSIGNOR:

ASSIGNEE:

Aeras

International AIDS Vaccine Initiative, Inc.

By: *Jacqueline Shea*

By: _____

Name: *Jacqueline E. Shea, Ph.D.*
 CEO, Aeras

Name: _____

Title: _____

Title: _____

Date: *30th September 2018*

Date: _____

IN WITNESS WHEREOF, the undersigned have caused this Assignment and Assumption to be duly executed effective as of the date first set forth above.

ASSIGNOR:

ASSIGNEE:

Aeras

International AIDS Vaccine Initiative, Inc.

By: _____

By:  _____

Name: _____

Name: Labeeb Abboud

Title: _____

Title: General Counsel & Senior Vice President

Date: _____

Date: September 28, 2018

**SCHEDULE A
ASSIGNED PATENTS AND TRADEMARKS**

PATENTS:

Table A.4.1 Family 002

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00221	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	US	11/755,936 (5/31/07)	2008-0095794 (4/24/08)	7,666,656 (2/23/10)	Issued
189107.00231	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	US	12/650,606 (12/31/09)	2010-0233213 (9/16/10)	8,043,857 (10/25/11)	Issued
189107.00203	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	EP	05858631.4 (11/23/05)	EP 1827504 (9/5/07)	EP 1827504 (5/11/11)	Issued
189107.00204	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	JP	2007-545507 (11/23/05)		5713523 (3/11/15)	Issued
189107.00205	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	TW	20050141904 (11/29/05)		1456057 (10/11/14)	Issued
189107.00206	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	PE	1391.2005 (11/30/05)			Pending
189107.00207	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	AP	2007/004033 (11/23/05)			Allowed
189107.00208	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	AU	2005338353 (11/23/05)		2005338353 (7/28/11)	Issued

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00209	Mycobacterium, Method Of Enabling A Mycobacterium To Escape From Endosomes And Vaccine Preparation	BR	PI 0518091-0 (11/23/05)			Allowed
189107.00215	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	CA	2,589,204 (11/23/05)		2,589,204 (10/29/13)	Issued
189107.00216	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	CN	200580041438.3 (6/1/07)		ZL20058004 1438.3 (6/26/13)	Issued
189107.00217	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	EA	200701128 (11/23/05)		012434 (10/30/09)	Issued
189107.00218	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	ID	W-00200701728 (11/23/05)			Allowed
189107.00219	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	IN	3677/2007 (11/23/05)		258525 (1/17/14)	Issued
189107.00225	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	KR	10-2007- 7015173 (11/23/05)		10-1329323 (11/7/13)	Issued
189107.00226	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	MX	2007/006551 (11/23/05)		MX 283767 (2/8/11)	Issued
189107.00227	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	NG	2007/820 (11/23/05)		2007/820 (5/31/07)	Issued
189107.00228	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	OA	1200700206 (11/23/05)		14103 (6/25/09)	Issued
189107.00229	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	ZA	2007/04765 (11/23/05)		2007/04765 (9/25/08)	Issued
189107.00235	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	BE	EP 1827504 (11/23/05)		EP 1827504 (5/11/11)	Issued

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00236	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	CH	EP 1827504 (11/23/05)		EP 1827504 (5/11/11)	Issued
189107.00237	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	DE	EP 1827504 (11/23/05)		EP 1827504 (5/11/11)	Issued
189107.00238	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	DK	EP 1827504 (11/23/05)		EP 1827504 (5/11/11)	Issued
189107.00239	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	ES	EP 1827504 (11/23/05)		EP 1827504 (5/11/11)	Issued
189107.00245	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	FR	EP 1827504 (11/23/05)		EP 1827504 (5/11/11)	Issued
189107.00246	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	GB	EP 1827504 (11/23/05)		EP 1827504 (5/11/11)	Issued
189107.00247	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	IT	EP 1827504 (11/23/05)		EP 1827504 (5/11/11)	Issued
189107.00248	Recombinant BCG Strains With Enhanced Ability To Escape The Endosome	NL	EP 1827504 (11/23/05)		EP 1827504 (5/11/11)	Issued

Table A.4.2 Family 003

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00301	Transformed Bacterium Lacking Selectable Marker And Overexpression Of Antigens In Mycobacteria	US	11/288,424 (11/29/05)	2006-0121054 (6/8/06)	7,625,572 (12/1/09)	Issued

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00311	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	US	11/755,768 (5/31/07)	2008-0286852 (11/20/08)	7,829,104 (11/9/10)	Issued
189107.00303	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	EP	05852317.6 (11/29/05)	EP 1817061 (8/15/07)	EP 1817061 (7/27/11)	Issued
189107.00304	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	JP	2007-544419 (11/29/05)		5461776 (1/24/14)	Issued
189107.00305	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	AP	2007/004021 (11/29/05)		AP 2869 (3/31/14)	Issued
189107.00306	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	AU	2005312062 (11/29/05)		2005312062 (3/1/12)	Issued
189107.00307	Transformed Bacterium Or Progeny Thereof, Method Of Transforming A Bacterium, Transformed Mycobacterium Or Progeny Thereof And Vaccine Comprising A Transformed Mycobacterium Or Progeny Thereof	BR	PI 0518080-5 (11/29/05)			Allowed
189107.00308	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	CA	2,587,507 (11/29/05)		2,587,507 (11/19/13)	Issued

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00309	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	CN	200580041437.9 (6/1/07)		ZL 200580041437.9 (4/3/13)	Issued
189107.00315	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	EA	200701130 (11/29/05)		012182 (8/28/09)	Issued
189107.00316	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	ID	W-00200701726 (11/29/05)		IDP000037928 (3/4/15)	Issued
189107.00317	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	IN	3686/DELNP/2007 (11/29/05)		262398 (8/20/14)	Issued
189107.00318	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	KR	10-2007-7015172 (11/29/05)		10-1382215 (4/1/14)	Issued
189107.00319	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	MX	2007/006552 (11/29/05)		277803 (8/3/10)	Issued
189107.00325	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	NG	302/07 (11/29/05)		17063 (5/23/07)	Issued
189107.00326	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	OA	120700206 (11/29/05)		13805 (5/30/08)	Issued
189107.00327	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	ZA	2007/04764 (11/29/05)		2007/04764 (9/25/08)	Issued

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00328	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	BE	EP 1817061 (11/29/05)		EP 1817061 (7/27/11)	Issued
189107.00329	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	CH	EP 1817061 (11/29/05)		EP 1817061 (7/27/11)	Issued
189107.00335	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	DE	EP 1817061 (11/29/05)		EP 1817061 (7/27/11)	Issued
189107.00336	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	DK	EP 1817061 (11/29/05)		EP 1817061 (7/27/11)	Issued
189107.00337	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	ES	EP 1817061 (11/29/05)		EP 1817061 (7/27/11)	Issued
189107.00338	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	FR	EP 1817061 (11/29/05)		EP 1817061 (7/27/11)	Issued
189107.00339	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	GB	EP 1817061 (11/29/05)		EP 1817061 (7/27/11)	Issued
189107.00345	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	IT	EP 1817061 (11/29/05)		EP 1817061 (7/27/11)	Issued
189107.00346	Electroporation Of Mycobacterium And Overexpression Of Antigens In Mycobacteria	NL	EP 1817061 (11/29/05)		EP 1817061 (7/27/11)	Issued

Table A.4.3 Family 004

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00411	Bacterial Packaging Strains Useful For Generation And Production Of Recombinant Double-Stranded RNA Nucleocapsids And Uses Thereof	US	11/284,817 (11/23/05)	2006-0115493 (6/1/06)	8,053,568 (11/8/11)	Issued
189107.00405	Bacterial Packaging Strains Useful For Generation And Production Of Recombinant Double-Stranded RNA Nucleocapsids And Uses Thereof	CN	200580041153.X (5/30/07)		ZL200580041153.X (8/10/11)	Issued
189107.00406	Bacterial Packaging Strains Useful For Generation And Production Of Recombinant Double-Stranded RNA Nucleocapsids And Uses Thereof	ZA	2007/04766 (11/23/05)		2007/04766 (9/25/08)	Issued

Table A.4.4 Family 005

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00501	Webbed Immunogens Comprising Recombinant Human Immunodeficiency Virus (HIV) Envelope Glycoproteins And The M9 Scorpion Toxin	US	11/445,455 (6/2/06)	2007-0014814 (1/18/07)	7,537,769 (5/26/09)	Issued

Table A.4.5 Family 006

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00605	Process For Stabilization Of Bacterial Cells Using Tyloxapol	ZA	2008/03526 (9/26/06)		2008/03526 (10/28/09)	Issued

Table A.5.6 Family 007

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00701	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	US	11/945,680 (11/27/07)	2009-0136534 (5/28/09)	7,670,609 (3/2/10)	Issued
189107.00711	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	US	12/618,037 (11/13/09)	2011-0117133 (5/19/11)	8,361,482 (1/29/13)	Issued
189107.00703	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	EP	08853526.5 (11/26/08)	EP 2235163 (10/6/10)	EP 2235163 (12/12/13)	Issued

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00705	Recombinant BCG Tuberculosis Vaccine For Eliciting Immune Responses To Mycobacterium Tuberculosis	CN	200880124600.1 (11/26/08)		ZL200880124600.1 (11/23/16)	Issued
189107.00706	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	IN	4543/2010 (11/26/08)			Pending
189107.00707	Recombinant BCG Tuberculosis Vaccine For Eliciting Immune Responses To Mycobacterium Tuberculosis	ZA	2010/04475 (11/26/08)		2010/04475 (9/28/11)	Issued
189107.00708	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	BE	EP 2235163 (12/12/13)		EP 2235163 (12/12/13)	Issued
189107.00709	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	DE	EP 2235163 (12/12/13)		EP 2235163 (12/12/13)	Issued
189107.00715	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	DK	EP 2235163 (12/12/13)		EP 2235163 (12/12/13)	Issued

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00716	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	ES	EP 2235163 (12/12/13)		EP 2235163 (12/12/13)	Issued
189107.00717	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	FR	EP 2235163 (12/12/13)		EP 2235163 (12/12/13)	Issued
189107.00718	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	GB	EP 2235163 (12/12/13)		EP 2235163 (12/12/13)	Issued
189107.00719	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	IT	EP 2235163 (12/12/13)		EP 2235163 (12/12/13)	Issued
189107.00725	Novel Recombinant BCG Tuberculosis Vaccine Designed To Elicit Immune Responses To Mycobacterium Tuberculosis In All Physiological Stages Of Infection And Disease	NL	EP 2235163 (12/12/13)		EP 2235163 (12/12/13)	Issued

Table A.4.7 Family 008

Docket Number	Title	Country	Application Number Filing date	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00801	Methods To Increase Transgene Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response	US	11/854,027 (9/12/07)	2009-0068222 (3/12/09)	7,608,256 (10/27/09)	Issued
189107.00811	Methods To Increase Transgene Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response	US	12/558,137 (9/11/09)	2010-0003219 (1/7/10)	7,883,696 (2/8/11)	Issued
189107.00821	Methods To Increase Transgene Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response	US	12/964,830 (12/10/10)	2011-0086066 (4/14/11)	8,414,884 (4/9/13)	Issued
189107.00841	Methods To Increase Transgene Expression From Bacterial-Based Delivery Systems By Co-Expressing Suppressors Of The Eukaryotic Type I Interferon Response	US	13/858,289 (4/8/13)	2013-0224242 (8/29/13)	8,658,136 (2/25/14)	Issued
189107.00804	Methods To Increase The Transgene Expression From Bacterial-Based Delivery System By Co-Expressing Suppressors Of Eukaryotic Type I Interferon Response	JP	2010-524977 (9/12/08)		5665541 (12/19/14)	Issued

Table A.4.8 Family 009

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.00901	Malaria Vaccine Compositions And Constituents Which Elicit Cell Mediated Immunity	US	12/863,040 (5/5/11)	2011-0206714 (8/25/11)	8,728,492 (5/20/14)	Issued
189107.00904	Malaria Vaccine Compositions And Constituents Which Elicit Cell Mediated Immunity	JP	2010-543174 (1/12/09)		5573679 (7/11/14)	Issued
189107.00905	Recombinant Antigenic Polypeptide, Recombinant Antigenic Peptide, Nucleic Acid And Method Of Immunizing An Individual Against Malaria	BR	PI 0905729-3 (1/12/09)	2446 (11/21/17)		Pending

Table A.4.9 Family 010

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.01001	Generation Of New BCG Vaccine Strains Protecting Against The Establishment Of Latent Mycobacterium Tuberculosis Infection And Reactivation From The Latent Or Persistent State	US	11/939,144 (11/13/07)	2009-0123492 (5/14/09)	7,935,354 (5/3/11)	Issued

Table A.4.10 Family 012

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.01201	Stable, Spray Dried, Immunogenic, Viral Compositions	US	13/321,048 (11/17/11)	2012-0058162 (3/8/12)	9,610,343 (4/4/17)	Issued
189107.01211	Stable, Spray Dried, Immunogenic, Viral Compositions	US	15/438,881 2/22/17	2018-0015158 (1/18/18)		Pending
189107.01203	Stable, Spray Dried Immunogenic Viral Compositions	EP	10778366.4 5/20/10	EP 2432502 (3/28/12)	EP 2432502 (1/3/18)	Issued
189107.01206	Stable, Spray Dried Immunogenic Viral Compositions	CN	201610217396.4 4/8/16			Pending
189107.01207	Stable, Spray Dried Immunogenic Viral Compositions	HK	17100694.0 1/9/17	HK1229210 (11/17/17)		Pending

Table A.4.11 Family 014

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.01401	Tuberculosis Compositions And Methods Of Using The Same	US	14/313,694 (6/24/14)	2014-0377300 (12/25/14)		Pending
189107.01403	Tuberculosis Compositions And Methods Of Using The Same	EP	14817274.5 (12/23/15)	3013364 (5/4/16)		Pending
189107.01404	Tuberculosis Compositions And Methods Of Using The Same	JP	2016-523852 (12/24/15)	P2016-529223A (9/23/16)		Pending
189107.01405	Tuberculosis Compositions And Methods Of Using The Same	CN	201480040735.5 (1/18/16)	CN105431166 (3/23/16)		Pending

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.01406	Tuberculosis Compositions And Methods Of Using The Same	IN	11433/2015 (12/15/15)	11433/2015 (4/29/16)		Pending
189107.01407	Tuberculosis Compositions And Methods Of Using The Same	ZA	2015/09262 (12/18/15)			Pending

Table A.4.12 Family 015

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.01501	Recombinant Cytomegalovirus Vectors As Vaccines For Tuberculosis	US	15/628,921 (6/21/17)	2018-0016599 (1/18/18)		Pending
189107.01502	Recombinant Cytomegalovirus Vectors As Vaccines For Tuberculosis	WO	PCT/US17/38439 (6/21/17)			NP due 12/22/18

Table A.4.13 Family 016

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.01601	Tuberculosis Compositions And Methods Of Treating Or Preventing Tuberculosis	US	15/624,853 (6/16/17)	2017-0362284 (12/21/17)		Pending
189107.01602	Tuberculosis Compositions And Methods Of Treating Or Preventing Tuberculosis	WO	PCT/US17/37824 (6/16/17)			NP due 12/16/18

Table A.4.14 Family 018

Docket Number	Title	Country	Application Number (Filing date)	Publication Number (Publication date)	Patent Number (Issue Date)	Status
189107.01800	Tuberculosis Antigen Cassettes	US	62/573,432 (10/17/17)			Pending

TRADEMARKS:

NONE